The new 350,000 square-foot Mesa hub is expected to expand the compounding pharmacy’s national fulfillment and advanced compounding capabilities.
Strive Pharmacy, a compounding pharmacy, has begun construction of a new 350,000-square-foot facility in Mesa, AZ that will now serve as its HQ and advanced compounding plant.1
According to the company, the growth in space is a symbol of something greater, including an interest in finding new ways to boost patient care and developing the workforce. The Mesa plant will be responsible for not only handling fulfillment on a national scale, but increasing manufacturing capacity, while opening up new jobs.
In other words, the new facility is expected to better position Strive to meet both current and rising demand for personalized care by allowing the pharmacy to quickly adapt to evolving patient needs, industry innovations, and any medication shortages that could come to light.
“This new headquarters is an investment in Arizona, in our team, and in the future of patient-focused medicine,” said Nate Hill, Strive Pharmacy’s CEO and co-founder.“Arizona is where Strive started, and this project allows us to build the infrastructure, technology, and talent necessary to meet growing demand while staying true to our mission never to settle, especially when people’s health is at stake.”
More specific details surrounding the facility—such as areas within the space that will focus on compounding or fulfillment, training centers, and other administrative operations—are forthcoming, but the company is reportedly anticipated to committed for the long-haul.
“When we invest in our facilities, we’re investing directly in patients and providers,” commented Mike Walker, president and co-founder. “This headquarters will anchor the systems, quality controls, and service levels that define Strive. It’s a home built for the next decade of innovation. At Strive, we’re not simply growing, we’re evolving. Every square foot we build is designed to improve access, elevate quality, and deliver care with transparency and compassion.”
The news follows Strives’ recent expansion and transfer of its Tampa location, along with the purchase of 275,000-square-foot current good manufacturing practice (cGMP) production site in Alachua, FL. Among various services, the newly acquired building—valued by various pharma manufacturers at upwards of $500 million—will offer production and fulfillment of biologics and active pharmaceutical ingredients (APIs).2
The name may also sound familiar, as this past October, a federal judge dismissed a lawsuit against Strive that was filed by Eli Lilly, which was originally for the false and deceptive online advertising of tirzepatide—the active ingredient in Mounjaro and Zepbound.3,4,5
Although tirzepatide was removed from the FDA’s
Earlier this year, Pharma Commerce spoke with Donald Prentiss, founder and CEO of Qualthera, a 503A pharmacy partners with 503B facilities. He explained7 the role that compounding pharmacies play in bridging the gap for patients in need of their medication, sharing that, “Back in October is when the FDA indicated that it was now off of shortage. There was some litigation out there from the Outsourcing Facilities Association and others that argue that it was not actually off of shortage in the market, because a lot of pharmacies were getting feedback that patients were still having trouble getting that, since they couldn't get it from their wholesalers to give it to their patients. You saw some back and forth there.
“ … If I'm only allowed to make something when it's on shortage, I have to be fairly certain that it's going to be on shortage a good while, so I can recoup my cost, while also making some money, because they are a business, they have to make good business decisions. That's a little bit of the rub between compounding pharmacies and the FDA and drug manufacturers—compounding pharmacies can step in to fill these gaps, only when on shortage, but guess what? This is off shortage now. You stop making it, and now you're stuck, holding back with your cost. … “There were still questions of, if we jump in and make these medications, how long and what kind of tail can we expect when they come off as shortage to again, recoup our costs? There were was a lot of back-and-forth discussion on that, in order to help protect everyone's interests.”
References
1. Strive Pharmacy Breaks Ground on New 350,000 Sq. Ft. Arizona Headquarters and Compounding Facility, Strengthening Its National Leadership in Patient-Focused Innovation. Access Newswire. December 2, 2025. Accessed December 2, 2025.
2. Strive Pharmacy Expands Footprint with Acquisition of Alachua Facility and New Tampa Location, Cementing Leadership in Patient-Focused Compounding Innovation. Access Newswire. November 4, 2025. Accessed December 2, 2025.
3. Eli Lilly and Company v. Strive Pharmacy LLC lawsuit (posted by Partnership for Safe Medicines). US District Court for the District of Delaware. April 1, 2025. Accessed December 2, 2025.
4. Eli Lilly and Company v Strive Pharmacy LLC Memorandum Ipinion. Justia US Law. October 8, 2025. Accessed December 2, 2025.
5. Wanneh G. DE Judge Dismisses Lilly Suit Against AZ Pharmacy Compounder. InsideHealthPolicy. October 9, 2025. Accessed December 2, 2025.
6. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. US Food & Drug Administration. March 10, 2025. Accessed December 2, 2025.
7. Saraceno N. Clearing Up the Competition Myth. Pharmaceutical Commerce. January 17, 2025. Accessed December 2, 2025.
